Concurrent for Ozempic: Amerikaans farmabedrijf comes with obesitasmedicijn | Economy

Zepbound is the obesity treatment from the American farm of Eli Lilly. On Tuesday there was a big light from the American farm on the Food and Drug Administration (FDA). The medicine is good for men with a BMI of higher than 30 of for men with a BMI of higher than 27 the worst parts with a high blood pressure of sleep. On the name of Mounjaro wordt the middle of the disease for type 2 diabetes.

According to Eli Lilly, the doctor is now available in the VS for mensen the camps with obesity. The middle of the day has been administered every week with an injection. It costs 1,060 dollars (990 euros) per month. This is about 20 percent of the goods sold in the Middel Wegovy van the Deense farmabedrijf Novo Nordisk.

With the American new brand, Novo Nordisk has a concurrent connection. Wegovy laat a weight loss tot 15 percent optekenen, according to the report ‘De Tijd’.

Thanks to the sale of Mounjaro, the first negen amount is 3 billion dollars (2.8 million euros) opleverde, Eli Lilly bought a market price of 560 million dollars (525 million euros). werelds waardevolste farmabedrijf, writing de Amerikaanse zakenkrant ‘The Wall Street Journal’.

Experts say that the material used in the German language and the American farming system can be loosened, so the German language is used in a fight with signals from Ozempic and Wegovy. The world has a large size.

ttn-39